Roche Holding AG
Roche Holding AG, commonly referred to as Roche, is a leading global healthcare company headquartered in Basel, Switzerland (CH). Founded in 1896, Roche has established itself as a pioneer in the pharmaceutical and diagnostics industries, focusing on innovative solutions for oncology, immunology, infectious diseases, and personalised medicine. With a strong presence in Europe, North America, and Asia, Roche is renowned for its commitment to research and development, producing unique products such as targeted therapies and advanced diagnostic tools. The company’s robust portfolio includes well-known medications like Herceptin and Avastin, which have transformed cancer treatment. Roche's dedication to innovation has earned it a prominent market position, consistently ranking among the top pharmaceutical companies globally. Its achievements in personalised healthcare and diagnostics underscore its role as a leader in advancing medical science and improving patient outcomes.
DitchCarbon Score
How does Roche Holding AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Roche Holding AG's score of 77 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Roche Holding AG's reported carbon emissions
In 2023, Roche Holding AG reported total carbon emissions of approximately 6,000,000,000 kg CO2e, with emissions distributed across various scopes: 240,266,000 kg CO2e (Scope 1), 98,480,000 kg CO2e (Scope 2), and a significant 5,978,508,000 kg CO2e (Scope 3). The company has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions by 70% by 2029 from a 2022 baseline, and to achieve a 90% reduction by 2045. For Scope 3 emissions, Roche targets a 22.5% reduction by 2029 and a 90% reduction by 2045. Roche's long-term goal is to reach net-zero emissions across its entire value chain by 2045. This commitment aligns with the Science Based Targets initiative (SBTi) and reflects the company's dedication to sustainable practices within the pharmaceuticals and biotechnology sector. The company is also focused on ensuring that 70% of its suppliers have science-based targets by 2029, further enhancing its sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 249,350,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 114,452,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 6,402,719,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Roche Holding AG is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
